HHUCHMED在上海Hutchison出售了45%的股份 608M美元,用于资助新的癌症和免疫疾病治疗。 HUTCHMED sold a 45% stake in Shanghai Hutchison for $608M to fund new cancer and immunological disease treatments.

HUCHMED是一家生物制药公司,以6.08亿美元的价格在上海哈奇森制药公司出售了45%的股份,重点开发新的癌症和免疫疾病治疗方法。 HUTCHMED, a biopharmaceutical company, sold a 45% stake in Shanghai Hutchison Pharmaceuticals for $608 million to focus on developing new cancer and immunological disease treatments. 该公司计划利用这些收益推进其抗体定向治疗方案,预计第一位将在今年接受临床试验。 The company plans to use the proceeds to advance its antibody-targeted therapy programs, with the first expected to enter clinical trials this year. HUCHMED将在SHPL修养后保留5%的股权。 HUTCHMED will retain a 5% equity interest in SHPL post-divestment.